Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Active as of 2024-04-27 |
Resource Citation "179622" Version "1" Updated "2023-11-26 22:35:16+0000"
url: https://fevir.net/resources/Citation/179622
identifier: FEvIR Object Identifier/179622, https://pubmed.ncbi.nlm.nih.gov/26002607
version: 1.0.0-ballot
title: 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.
status: active
date: 2024-04-27 20:42:39+0000
publisher: HL7 International / Clinical Decision Support
contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss
description: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.
| Code | Value[x] |
| FEvIR Platform Use (Details: http://hl7.org/fhir/citation-classification-type code fevir-platform-use = 'FEvIR Platform Use', stated as 'FEvIR Platform Use') | Medline Base (Citation Artifact Classifier#medline-base) |
jurisdiction: World (m49.htm#001)
copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/
approvalDate: 2016-04-21
lastReviewDate: 2020-02-06
author: Computable Publishing®: MEDLINE-to-FEvIR Converter:
classification
type: Citation Source (Citation Classification Type#citation-source)
classifier: MEDLINE ()
classification
type: MEDLINE Citation Owner (Citation Classification Type#medline-owner)
classifier: National Library of Medicine, Index Section (elements_descriptions.html#owner_value#NLM)
currentState: Medline Citation Status of Medline (Citation Status Type#medline-medline), PubMed PublicationStatus of ppublish (Citation Status Type#pubmed-publication-status-ppublish)
statusDate
activity: PubMed Pubstatus of Received (Citation Status Type#pubmed-pubstatus-received)
period: ?? --> 2015-03-21
statusDate
activity: PubMed Pubstatus of Accepted (Citation Status Type#pubmed-pubstatus-accepted)
period: ?? --> 2015-05-13
statusDate
activity: PubMed Pubstatus of Entrez (Citation Status Type#pubmed-pubstatus-entrez)
period: ?? --> 2015-05-24 06:00:00+0000
statusDate
activity: PubMed Pubstatus of Pubmed (Citation Status Type#pubmed-pubstatus-pubmed)
period: ?? --> 2015-05-24 06:00:00+0000
statusDate
activity: PubMed Pubstatus of Medline (Citation Status Type#pubmed-pubstatus-medline)
period: ?? --> 2016-04-22 06:00:00+0000
citedArtifact
identifier:
https://pubmed.ncbi.nlm.nih.gov/26002607,https://www.ncbi.nlm.nih.gov/pmc//PMC4511224,https://doi.org/10.1093/annonc/mdv245, pii/S0923-7534(19)31866-6Titles
Type Language Text Primary title (Title Type#primary) English (Tags for the Identification of Languages#en) Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. Abstracts
Text Copyright Following the results of the TAX-327 study, questions have been raised as to whether administering chemotherapy to men with prostate cancer before symptomatic disease progression when receiving standard hormonal treatment can improve the duration and quality of patient survival. The GETUG-AFU-15 and CHAARTED studies both assessed the efficacy and tolerability of androgen deprivation therapy (ADT) with or without docetaxel in men with metastatic hormone-naive prostate cancer. Both studies included a mix of patients with de novo metastatic disease (∼75%) and patients who developed metastases following treatment of localized disease. A short course of ADT was allowed in both trials prior to accrual. Key differences between the two studies include the number of patients with high-volume metastases (GETUG-AFU-15: 52%; CHAARTED: 65%) and number of docetaxel cycles (GETUG-AFU-15: up to nine cycles; CHAARTED six cycles). Both studies reported an improvement in progression-free survival with docetaxel plus ADT versus ADT alone. The GETUG-AFU-15 did not find a significant difference in the primary end point of overall survival (OS) {hazard ratio (HR) 0.9 [95% confidence interval (CI) 0.7-1.2]; P = 0.44} for ADT plus docetaxel versus ADT alone. The CHAARTED study met the primary end point of OS [HR 0.61 (95% CI 0.47-0.80); P = 0.0003], and in a subset analysis reported the greatest improvement in OS for patients with high-volume disease [HR 0.60 (95% CI 0.45-0.81); P = 0.0006]. The following article debates the results from the GETUG-AFU-15 and CHAARTED studies and asks whether medical practice should be changed for patients with metastatic hormone-naive prostate cancer based on the results of one positive study. © The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Wu JN, Fish KM, Evans CP et al. . No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer 2013; 120(6): 818–823.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/24258693/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/24258693relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Center MM, Jemal A, Lortet-Tieulent J et al. . International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61(6): 1079–1092.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/22424666/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/22424666relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Cullen J, Elsamanoudi S, Brassell SA et al. . The burden of prostate cancer in Asian nations. J Carcinog 2012; 11: 7.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/22529743/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/22529743relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Patrikidou A, Loriot Y, Eymard J-C et al. . Who dies from prostate cancer? Prostate Cancer Prostatic Dis 2014; 17(4): 348–352.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/25311767/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/25311767relatesTo
type: cites
citation: Sweeney C, Carducci MA, Eisenberger MA et al. . Chemohormonal therapy versus hormonal therapy for hormone naive newly metastatic prostate cancer: ECOG-led randomized trial. Ann Oncol 2014; (Suppl 4): Abstr 7560.
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Gravis G, Fizazi K, Joly F et al. . Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14(2): 149–158.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/23306100/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/23306100relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Ahmed M, Li L-C. Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective. Int J Urol 2013; 20(4): 362–371.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/23163774/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/23163774relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Tannock IF, de Wit R, Berry WR et al. . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351(15): 1502–1512.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/15470213/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/15470213relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Berthold DR, Pond GR, Soban F et al. . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26(2): 242–245.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/18182665/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/18182665relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Petrylak DP, Tangen CM, Hussain MHA et al. . Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351(15): 1513–1520.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/15470214/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/15470214relatesTo
type: cites
citation: Gravis G, Boher J-M, Joly F et al. . Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (Pca): long-term analysis of the GETUG-AFU-15 phase III trial. J Clin Oncol 2015; (GU suppl): abstr 140.
relatesTo
type: cites
citation: Sweeney C, Chen Y-H, Carducci MA et al. . Impact on overall survival with chemohormonal therapy versus hormone therapy for hormone-sensitive newly metastatic prostate cancer: an ECOG-led phase III randomized trial. J Clin Oncol 2014; 32(5s): abstr LBA2.
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Fitzpatrick JM, de Wit R. Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer. Eur Urol 2014; 65(6): 1198–1204.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/23910941/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/23910941relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Harris WP, Mostaghel EA, Nelson PS, Montgomery RB. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009; 6(2): 76–85.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/19198621/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/19198621relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: van Soest RJ, van Royen ME, de Morrée ES et al. . Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer 2013; 49(18): 3821–3830.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/24200698/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/24200698relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Mezynski J, Pezaro C, Bianchini D et al. . Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol 2012; 23(11): 2943–2947.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/22771826/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/22771826relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Nakouzi Al N, Le Moulec S, Albiges L et al. . Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol 2014; 66: e71–e72.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/25012524/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/25012524relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Payne H, Bahl A, Mason M et al. . Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities. BJU Int 2012; 110(5): 658–667.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/22429837/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/22429837relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Droz J-P, Aapro M, Balducci L et al. . Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 2014; 15(9): e404–e414.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/25079103/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/25079103relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Stone P, Hardy J, Huddart R et al. . Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer 2000; 36(9): 1134–1141.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/10854947/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/10854947relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Nguyen PL, Alibhai SMH, Basaria S et al. . Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 2015; 67(5): 825–836.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/25097095/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/25097095relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Loriot Y, Fizazi K. Taxanes: still a major weapon in the armamentarium against prostate cancer. Eur Urol 2013; 63(6): 983–985.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/23395593/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/23395593relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Gerritse FL, Meulenbeld HJ, Roodhart JML et al. . Analysis of docetaxel therapy in elderly (≥70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study. Eur J Cancer 2013; 49(15): 3176–3183.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/23849828/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/23849828relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Fizazi K, Abrahamsson P-A, Ahlgren G et al. . Achievements and perspectives in prostate cancer phase 3 trials from Genitourinary Research Groups in Europe: introducing the Prostate Cancer Consortium in Europe. Eur Urol 2015; 67(5): 904–912.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/25218582/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/25218582relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Eisenberger MA, Blumenstein BA, Crawford ED et al. . Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339(15): 1036–1042.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/9761805/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/9761805relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Crawford ED, Eisenberger MA, McLeod DG et al. . A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321(7): 419–424.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/2503724/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/2503724relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Hussain M, Tangen CM, Berry DL et al. . Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013; 368(14): 1314–1325.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/23550669/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/23550669relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Millikan RE, Wen S, Pagliaro LC et al. . Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol 2008; 26(36): 5936–5942.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/19029421/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/19029421relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Tait C, Moore D, Hodgson C et al. . Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival. BJU Int 2014; 114(6b): E70–E73.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/24589330/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/24589330relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Gravis G, Boher J-M, Fizazi K et al. . Prognostic factors for survival in noncastrate metastatic prostate cancer: validation of the Glass Model and development of a novel simplified prognostic model. Eur Urol 2014. Sep 29 [epub ahead of print], doi: 10.1016/j.eururo.2014.09.022.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/25277272/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/25277272relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: James ND, Spears MR, Clarke NW et al. . Survival with newly diagnosed metastatic prostate cancer in the ‘docetaxel era’: data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol 2015; 67(6): 1028–1038.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/25301760/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/25301760relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997; 57(2): 229–233.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/9000560/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/9000560relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4(4): 253–265.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/15057285/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/15057285relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Mercader M, Sengupta S, Bodner BK et al. . Early effects of pharmacological androgen deprivation in human prostate cancer. BJU Int 2007; 99(1): 60–67.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/17227493/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/17227493relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Ioannidis J. Why most published research findings are false. PLoS Med 2005; 2(8): e124.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/16060722/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/16060722relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Templeton AJ, Vera-Badillo FE, Wang L et al. . Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol 2013; 24(12): 2972–2977.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/24126362/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/24126362relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Gravis G, Marino P, Joly F et al. . Patients self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15). Eur J Cancer 2014; 50(5): 953–962.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/24424105/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/24424105publicationForm
PublishedIns
Type Identifier Title PublisherLocation Periodical (Published In Type#D020492) Electronic ISSN Type/1569-8041, ISOAbbreviation/Ann Oncol, ISSN Linking/0923-7534, Medline Title Abbreviation/Ann Oncol, NLM Unique ID/9007735 Annals of oncology : official journal of the European Society for Medical Oncology England citedMedium: Internet (Cited Medium#internet)
volume: 26
issue: 8
articleDate: 2015-08
publicationDateText: 2015-Aug
language: English (Tags for the Identification of Languages#en)
pageString: 1660-7
publicationForm
citedMedium: Internet without issue (Cited Medium#internet-without-issue)
articleDate: 2015-05-22
webLocation
classifier: Abstract (Artifact Url Classifier#abstract)
webLocation
classifier: DOI Based (Artifact Url Classifier#doi-based)
classification
type: Publishing Model (Cited Artifact Classification Type#publishing-model)
classifier: Print Electronic (Citation Artifact Classifier#Print-Electronic)
classification
type: Keyword (Cited Artifact Classification Type#keyword)
artifact: #
content
classifier: ADT ()
content
classifier: de novo metastatic ()
content
classifier: docetaxel ()
content
classifier: hormone-naive ()
content
classifier: prostate ()
classification
type: Chemical (Cited Artifact Classification Type#chemical)
classifier: Androgen Antagonists (#D000726), Taxoids (#D043823), Docetaxel (chemical-substances#15H5577CQD; #D000077143), Gonadotropin-Releasing Hormone (chemical-substances#33515-09-2; #D007987)
classification
type: MeSH Heading (Cited Artifact Classification Type#mesh-heading)
artifact: #
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Androgen Antagonists (#D000726)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: administration & dosage (#Q000008)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Antineoplastic Combined Chemotherapy Protocols (#D000971)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Bone Neoplasms (#D001859)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: drug therapy (#Q000188)
component
component
type: qualifier ()
classifier: secondary (#Q000556)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Disease Progression (#D018450)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Disease-Free Survival (#D018572)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Docetaxel (#D000077143)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Gonadotropin-Releasing Hormone (#D007987)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: agonists (#Q000819)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Humans (#D006801)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Male (#D008297)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Orchiectomy (#D009919)
freeToShare: true
Components
Type Classifier qualifier () is Major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Proportional Hazards Models (#D016016)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Prostatic Neoplasms (#D011471)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: drug therapy (#Q000188)
component
component
type: qualifier ()
classifier: pathology (#Q000473)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Standard of Care (#D059039)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Taxoids (#D043823)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: administration & dosage (#Q000008)
component
classification
type: Publication Type (Cited Artifact Classification Type#publication-type)
classifier: Journal Article (#D016428), Research Support, Non-U.S. Gov't (#D013485), Review (#D016454)
classification
type: Knowledge Artifact Type (Cited Artifact Classification Type#knowledge-artifact-type)
classifier: Journal Article (Citation Artifact Classifier#D016428)
artifactAssessment: : Classifier added by Computable Publishing LLC
classification
type: Citation Subset (Cited Artifact Classification Type#citation-subset)
classifier: IM (elements_descriptions.html#citationsubset#IM)
contributorship
complete: true
entry
name: K Fizazi
forenameInitials: K
affiliation: : Department of Cancer Medicine, Gustave Roussy, University of Paris Sud, Paris, France.
entry
name: C Jenkins
forenameInitials: C
affiliation: : Med Ed, RMC, Exeter, UK.
entry
name: I F Tannock
forenameInitials: IF
affiliation: : Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada ian.tannock@uhn.ca.
Generated Narrative: ArtifactAssessment #keywords0
artifact: #
content
classifier: ADT ()
content
classifier: de novo metastatic ()
content
classifier: docetaxel ()
content
classifier: hormone-naive ()
content
classifier: prostate ()
Generated Narrative: Practitioner #author0
name: K Fizazi
Generated Narrative: Practitioner #author1
name: C Jenkins
Generated Narrative: Practitioner #author2
name: I F Tannock
Generated Narrative: ArtifactAssessment #meshHeading0
artifact: #
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Androgen Antagonists (#D000726)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: administration & dosage (#Q000008)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Antineoplastic Combined Chemotherapy Protocols (#D000971)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Bone Neoplasms (#D001859)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: drug therapy (#Q000188)
component
component
type: qualifier ()
classifier: secondary (#Q000556)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Disease Progression (#D018450)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Disease-Free Survival (#D018572)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Docetaxel (#D000077143)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Gonadotropin-Releasing Hormone (#D007987)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: agonists (#Q000819)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Humans (#D006801)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Male (#D008297)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Orchiectomy (#D009919)
freeToShare: true
Components
Type Classifier qualifier () is Major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Proportional Hazards Models (#D016016)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Prostatic Neoplasms (#D011471)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: drug therapy (#Q000188)
component
component
type: qualifier ()
classifier: pathology (#Q000473)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Standard of Care (#D059039)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Taxoids (#D043823)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: administration & dosage (#Q000008)
component
IG © 2022+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#1.0.0-ballot based on FHIR 5.0.0. Generated 2024-04-27
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change